LJPC News Alert La Jolla Pharma (LJPC) 16.35 12/25/2014 06:4

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
La Jolla Pharma (LJPC) 16.35 $LJPC

Weakness Seen in La Jolla Pharmaceutical (LJPC): Stock Tumbles 17.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:41AM CST
La Jolla Pharmaceutical aw a big move last session, as the company’s shares fell by nearly 18% which reversed the trend for the company.
LJPC: 16.35 (-0.10), ARQL: 1.15 (+0.01)

Insider Buys And Sells: American Homes 4 Rent, Western Gas Partners
Asif Suria - at Seeking Alpha - Mon Dec 22, 3:50PM CST
Welcome to edition 235 of Insider Weekends. The prolific buying by insiders of energy companies lost some steam last week even as oil and energy stocks rebounded sharply along with the rest of the market. With the S&P 500 closing less than 5...
RH: 96.97 (-0.16), AMH: 17.34 (-0.07), VRTX: 115.15 (+1.40), CODI: 15.99 (-0.11), RES: 13.26 (-0.35), LJPC: 16.35 (-0.10), ICE: 221.73 (-1.70), WES: 73.08 (-0.25), ENH: 59.60 (-0.55), GHC: 877.19 (-0.76)

The 2015 Calendar Of NASH Trial Catalysts II: Galectin Therapeutics And La Jolla Pharmaceutical Co.
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 6:37AM CST

LJPC: 16.35 (-0.10), GALT: 3.19 (-0.04)

La Jolla up on angiotensin IP deal
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 11:58AM CST

LJPC: 16.35 (-0.10)

How La Jolla Pharmaceutical (LJPC) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:43AM CST
La Jolla Pharmaceutical is one stock that might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 72
LJPC: 16.35 (-0.10)

InsiderInsights.com Daily Round Up 12/15/14: NS, FCX, LJPC, OAS
InsiderInsights - at Seeking Alpha - Tue Dec 16, 2:28AM CST

VR: 41.51 (+0.19), GMCR: 137.65 (+1.10), LJPC: 16.35 (-0.10), FCX: 22.91 (+0.07), NS: 57.17 (+0.24), OSIS: 71.75 (+0.12), SNI: 78.54 (+0.85), GOOG: 528.77 (-1.82), HAIN: 117.25 (+0.23), WIW: 11.28 (+0.03), IDRA: 3.89 (+0.02), VRNS: 32.05 (+1.11), WRLD: 79.98 (+0.15), SNPS: 43.99 (+0.01), AI: 27.70 (-0.12), JGW: 10.70 (+0.04), OAS: 16.66 (-1.05), WIA: 11.55 (+0.06), CRM: 60.33 (-0.17)

La Jolla Pharmaceutical (LJPC) Jumps: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:11AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
ACRX: 6.61 (+0.06), LCI: 42.29 (+1.79), LJPC: 16.35 (-0.10), IG: 9.11 (-0.01)

La Jolla Pharmaceutical Company and the George Washington University Announce Exclusive Worldwide License Agreement
Business Wire - Tue Dec 09, 3:01PM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, and the George Washington University (GW), today announced that La Jolla and GW have entered into an exclusive worldwide license agreement for GW intellectual property rights covering the use of angiotensin II for the therapeutic treatment of patients with hypotension and shock. La Jolla plans to initiate a phase 3 registration program of LJPC-501, La Jolla's proprietary formulation of angiotensin II, in catecholamine-resistant hypotension (CRH) in the first quarter of 2015.
LJPC: 16.35 (-0.10)

LaJolla down on clinical trial results
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:10PM CST

LJPC: 16.35 (-0.10)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 11:48AM CST

IMDZ: 34.96 (+0.78), VTNR: 3.32 (-0.08), CYBR: 41.60 (+0.59), LJPC: 16.35 (-0.10), ZAZA: 3.20 (+0.70), XPLR: 6.60 (+0.06), FUEL: 17.08 (-0.12), NADL: 1.68 (-0.08), DWA: 22.72 (+0.05), CZR: 15.44 (+0.20), RCAP: 11.23 (+0.26), AMTX: 6.25 (-0.25), FLML: 17.01 (-0.98), AMOT: 23.01 (+0.35), RVNC: 16.65 (+0.42), LOCM: 1.15 (+0.03), JGW: 10.70 (+0.04), ICLD: 3.00 (-0.02), VPCO: 1.30 (-0.01), CSH: 22.16 (-0.46)

La Jolla Pharma -12.5% AH after Q3 report, Phase 2 study results
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 5:00PM CST

LJPC: 16.35 (-0.10)

La Jolla Pharmaceutical posts 3Q loss
Automated Insights - Wed Nov 12, 4:06PM CST
SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Wednesday reported a loss of $5.1 million, or 37 cents per share, in its third quarter.
LJPC: 16.35 (-0.10)

La Jolla Pharmaceutical misses by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:39PM CST

LJPC: 16.35 (-0.10)

Results from Phase 2 Study of GCS-100 in Chronic Kidney Disease Being Presented at American Society of Nephrology Kidney Week
Business Wire - Wed Nov 12, 3:14PM CST
--Improvement More Pronounced in Diabetic Patients
LJPC: 16.35 (-0.10)

La Jolla Pharmaceutical Company Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights
Business Wire - Wed Nov 12, 3:02PM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress and near-term milestones.
LJPC: 16.35 (-0.10)

La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 72.10 (+0.34), LCI: 42.29 (+1.79), BCRX: 11.83 (+0.76), LJPC: 16.35 (-0.10)

La Jolla Pharmaceutical Co. (LJPC) Jumps: Stock Rises 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:32AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise more than 10% on the day.
LJPC: 16.35 (-0.10), CEMP: 20.66 (+0.78), IG: 9.11 (-0.01), BIOD: 1.36 (-0.04)

5 Stocks Spiking on Unusual Volume
at The Street - Mon Oct 27, 6:00AM CDT
Keep these stocks trading on unusual volume on your trading radar.
SUSP: 46.00 (+0.69), LJPC: 16.35 (-0.10), IPCM: 45.95 (-0.19), EGBN: 35.96 (+0.12), CSL: 91.36 (+0.04)

La Jolla Pharmaceutical Company Announces Data Presentation at the American Society of Nephrology Kidney Week
Business Wire - Thu Oct 23, 3:01PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("the Company" or "La Jolla" , a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that an abstract of the results for the Company's Phase 2 clinical trial of GCS-100 in chronic kidney disease (CKD) has been selected by the American Society of Nephrology's (ASN) Program Committee for poster presentation at the Kidney Week Annual Meeting. Kidney Week will be held November 11-16, 2014 in Philadelphia, Pennsylvania.
LJPC: 16.35 (-0.10)

La Jolla (LJPC) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 9:41AM CDT
La Jolla (LJPC) Shares March Higher, Can It Continue?
LJPC: 16.35 (-0.10)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 147

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 51

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 84

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 39

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 67

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 76

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading

Top 5 Most Recently Viewed Articles

CEO of Cogent Communications to Showcase Company Updates

Updated Category News Views 112

Cogent Communications' CEO Will Share Insights at Key Conferences Cogent Communications Holdings, Inc. (NASDAQ: CCOI), recognized as one of the world's premier Internet service providers, has exciting news to share. Dave Schaeffer, the Chief Executive Officer, is set to present at two significant upcoming conferences, demonstrating leadership in the connectivity space....

Continue Reading
AnteraCapital 365 Unmasked: The Truth Behind Fraudulent Claims

Updated Category News Views 338

Understanding the Fraud of AnteraCapital 365 Be an informed investor – protect yourself against fraudulent schemes. The Canadian Investment Regulatory Organization (CIRO) has issued a warning regarding AnteraCapital 365. This fraudulent firm operates on multiple websites claiming to be associated with legitimate organizations, specifically, SIG North Trading, ULC. It is...

Continue Reading
Understanding the Liberty Broadband and Charter Merger Insights

Updated Category News Views 309

Rowley Law PLLC Conducts Investigation into Liberty Broadband Recently, Rowley Law PLLC has announced an investigation related to proposed acquisition activities involving Liberty Broadband Corporation (NASDAQ: LBRDA). This scrutiny comes amid news that Charter Communications, Inc. (NASDAQ: CHTR) intends to acquire Liberty Broadband. This proposed merger is set to impact...

Continue Reading
C3.ai Investors Urged to Act Now for Class Action Lawsuit

Updated Category News Views 198

C3.ai Investors Face Class Action Lawsuit The recent developments regarding C3.ai, Inc. (NYSE: AI) are significant for investors who have faced substantial losses. The former Attorney General of Louisiana, Charles C. Foti, Jr., alongside Kahn Swick & Foti, LLC, has reached out to stakeholders, reminding them of an impending deadline related to a class action lawsuit....

Continue Reading
JW Michaels Shares Insights on Salary Trends in Finance

Updated Category News Views 311

Understanding Executive Compensation in Financial Services Every year, companies and organizations strive to understand the nuances of compensation within the financial sector. JW Michaels & Co. recently released its latest Financial Services Market Data Report, offering valuable insights into executive remuneration practices for top-tier positions. This comprehensive...

Continue Reading